Covid-19 vaccine, mrna - Biologic Drug Details

Summary for covid-19 vaccine, mrna

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for covid-19 vaccine, mrna

Recent Clinical Trials for covid-19 vaccine, mrna

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Stanford University	PHASE4
Infectious Diseases Research Collaboration, Uganda	PHASE4
University of California, San Francisco	PHASE4

See all covid-19 vaccine, mrna clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for covid-19 vaccine, mrna Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for covid-19 vaccine, mrna Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biontech Manufacturing Gmbh	COMIRNATY	covid-19 vaccine, mrna	For Injection	125742	10,485,884	2033-03-25	DrugPatentWatch analysis and company disclosures
Biontech Manufacturing Gmbh	COMIRNATY	covid-19 vaccine, mrna	For Injection	125742	10,576,146	2038-03-15	DrugPatentWatch analysis and company disclosures
Biontech Manufacturing Gmbh	COMIRNATY	covid-19 vaccine, mrna	For Injection	125742	10,702,600	2040-02-28	DrugPatentWatch analysis and company disclosures
Biontech Manufacturing Gmbh	COMIRNATY	covid-19 vaccine, mrna	For Injection	125742	10,898,574	2038-03-21	DrugPatentWatch analysis and company disclosures
Biontech Manufacturing Gmbh	COMIRNATY	covid-19 vaccine, mrna	For Injection	125742	10,933,127	2040-05-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for covid-19 vaccine, mrna Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for covid-19 vaccine, mrna

Country	Patent Number	Estimated Expiration
Peru	20181530
World Intellectual Property Organization (WIPO)	2022086663
World Intellectual Property Organization (WIPO)	2015043613
Spain	2805873
South Korea	20220025105

Summary

Last updated: February 13, 2026

The mRNA-based COVID-19 vaccines, primarily from Pfizer-BioNTech and Moderna, have significantly influenced the global immunization landscape. Their market dynamics are driven by high efficacy, rapid development processes, and the necessity of booster doses amid evolving variants. Financial trajectories show initial explosive growth, followed by stabilization and growth shaped by booster campaigns, new formulations, and potential indications beyond COVID-19. The market is expected to decline gradually post-pandemic, but continued demand for updated vaccines sustains revenue streams. Diversification into other disease areas enhances long-term prospects.

---

What Are the Current Market Dynamics for mRNA COVID-19 Vaccines?

Market Penetration and Adoption

As of 2022, over 13 billion COVID-19 vaccine doses have been administered globally, with Pfizer-Bfizer/BioNTech’s BNT162b2 and Moderna’s mRNA-1273 accounting for a majority share ([1]). Early deployment was concentrated in developed countries, but global initiatives, including COVAX, expanded access.

Pfizer’s vaccine achieved Emergency Use Authorization (EUA) in December 2020, followed by Moderna’s in the same month. These approvals accelerated manufacturing and distribution, fueling rapid uptake.

Supply Chain and Manufacturing Capacity

Manufacturers scaled production swiftly. BioNTech and Moderna expanded their capacity from millions to billions of doses annually. Investments in new facilities and technology transfers increased output, but supply constraints persisted due to raw material shortages and logistical hurdles.

Regulatory and Policy Influences

Regulatory agencies responded with Emergency Use Authorizations and later full approvals (e.g., Pfizer’s full FDA approval in August 2021). Policies on booster doses and variant-specific formulations affected market flows.

Pricing and Reimbursement

Pricing strategies vary: developed countries negotiated bulk procurement agreements, establishing per-dose costs between $20 and $40. Reimbursement models depend on government health agencies and international donors, impacting revenue stability for manufacturers.

---

What Is the Financial Trajectory of the mRNA COVID-19 Vaccine Market?

Initial Growth Phase (2020-2021)

The market experienced rapid expansion as global vaccination campaigns launched. Pfizer and Moderna reported revenue peaks in 2021, with Pfizer’s vaccine generating approximately $36 billion and Moderna’s about $19 billion.

Post-Pandemic Stabilization and Decline

As vaccination coverage neared saturation in high-income countries, growth slowed. Market forecasts project a decline of 15-20% annually by 2024, as demand diminishes in mature markets.

Booster and Variant-Specific Vaccines

Booster doses sustain revenue, with estimates indicating that over 50% of doses administered globally are booster shots ([2]). Updated formulations targeting Omicron and other variants may command premium pricing, extending product life cycles.

Emerging Revenue Streams

Diversification occurs via license agreements, such as Moderna’s partnerships with Merck for vaccine technology, and pipeline expansion into other infectious diseases and cancer vaccines. The potential for platform technology to adapt to new indications offers long-term growth opportunities.

Long-term Outlook

Market analysts predict that COVID-19 vaccine revenues will decline to below $10 billion annually by 2025; however, the technology platform remains valuable for future vaccine development and other therapeutics ([3]).

---

How Do Market Forces Shape Future Prospects?

Vaccine Efficacy and Variants

The emergence of variants such as Omicron has prompted reformulations, impacting market stability. Vaccine effectiveness against new strains affects booster strategies and revenue.

Regulatory Developments

Full approvals and clear regulatory pathways influence commercialization timelines. National and regional policies on vaccine mandates and booster programs heavily influence market volume.

Competitive Landscape

Beyond Pfizer and Moderna, newer entrants and biosimilar manufacturers aim to develop competing mRNA vaccines, potentially reducing market share and pricing power.

Global Equity and Access

Disparities in vaccine access affect market expansion. WHO and GAVI efforts aim to distribute vaccines to low-income countries, but supply remains limited, constraining growth in emerging economies.

---

Key Takeaways

• The mRNA COVID-19 vaccine market experienced unprecedented growth in 2020-2021, driven by global vaccination efforts.
• Demand has plateaued in high-income countries; boosters sustain revenues, but declines are projected in the long-term.
• Manufacturing capacity expansions, vaccine reformulations, and diversification into other indications are critical to future growth.
• Regulatory approvals and public policy will shape market stability and expansion.
• Persistent global inequities and vaccine hesitancy pose challenges to market maturity and potential.

---

FAQs

1. What factors led to the rapid development of mRNA COVID-19 vaccines?

The mRNA platform allows swift design adjustments, enabling fast response to emerging pathogens. Prior research on mRNA technology provided a foundation. Emergency funding and streamlined regulatory pathways expedited rollout.

2. How reliant is the market on booster doses?

Booster doses constitute over half of recent administered vaccines. They prolong the market life of existing vaccines, but their necessity depends on variant evolution and vaccine durability.

3. Will new variants reduce the long-term profitability of mRNA vaccines?

Variants requiring updated vaccines can extend market relevance through reformulations. However, sustained efficacy challenges could diminish revenue if new vaccines are needed more frequently.

4. How are vaccine manufacturers planning for the post-pandemic period?

Manufacturers aim to pivot toward broader infectious disease vaccines and therapeutic applications, leveraging mRNA platform versatility for ongoing revenue streams.

5. What role do emerging markets play in the future of mRNA COVID-19 vaccines?

Emerging markets represent growth opportunities with strategic partnerships, although limited infrastructure and funding constraints slow adoption compared to high-income countries.

---

References

[1] World Health Organization. "(WHO Coronavirus (COVID-19) Dashboard)." 2022.

[2] CDC. "COVID-19 Vaccine Booster Doses." 2022.

[3] MarketsandMarkets. "mRNA Vaccines Market by Application, Geography, and End User." 2022.